Yang-I Lin

This inventor holds 47 USPTO granted patents, primarily in Platinum Complexes. Top assignees: American Cyanamid Company, Wyeth, Wyeth Holdings Corporation. Active years: 1977-2010.

USPTO Granted Patents = 47

% Patents Active = 89.4

Average Co-Inventor Count = 3.7

ph-index = 7

Forward Citations = 158(Granted Patents)

Location History:

Nanuet, NY (US) (1977 - 2001)
Jackson, NJ (US) (2009)
Tappan, NY (US) (1989 - 2010)

Company Filing History:

41 out of 3,580

American Cyanamid Company

Wyeth Holdings Corporation

patents

4. 1 out of 2

Wyeth, Five Giralda Farms

patents

5. 1 out of 834,307

Other

patents

Years Active: 1977-2010

Loading Chart...

Areas of Expertise:

Platinum Complexes

β-Lactamase Inhibitors

Nucleoside Antibiotics

Carbapenems

Cisplatin Analogs

Heterocyclic Compounds

Acridine Derivatives

Diamino Sugars

Metalloproteinase Inhibitors

Sulfonamide Derivatives

Process Improvement

Peptide Antibiotics

47 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 7812014 - Bicyclic 6-alkylidene-penems as β-lactamase inhibitors (2010-10-12),

2. 7595327 - Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase (2009-09-29),

3. 7112582 - Bicyclic 6-alkylidene-penems as β-lactamase inhibitors (2006-09-26),

4. 6727232 - Nucleoside peptide antibiotics of AA-896 (2004-04-27),

5. 6649756 - PROCESS IMPROVEMENT IN THE PREPARATION OF (4R, 5S, 6S)-3-[[(2R,3R)-2-[[[(S)-2-AMINO-3-METHYL-1-OXOBUTYL]AMINO]METHYL]TETRAHYDRO-3-FURANYL]THIO]-6-[(R)-1-HYDROXYETHYL]-4-METHYL-7-OXO-1-AZABICYCLO[3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID (2003-11-18),

6. 6395726 - 3,6-disubstituted penam sulfone derivatives (2002-05-28),

7. 6281365 - (Gem-heterocyclodimethanamine-n,n′)platinum complexes (2001-08-28),

8. 5750735 - 2-thiosubstituted carbapenems (1998-05-12),

9. 5744465 - Method of inhibiting a .beta.-lactamase enzyme by administering novel (1998-04-28),

10. 5623081 - Method for producing tetrahydrofuranyl compounds (1997-04-22),

11. 5602118 - 2-thiosubstituted carbapenems (1997-02-11),

12. 5210193 - Piperazine derivatives (1993-05-11),

13. 4996337 - Synthesis of cisplatin analogs (1991-02-26),

14. 4992449 - 7-(substituted)cycloalkylamino-1 (1991-02-12),

15. 4948894 - 8-fluoro and 7, 8, (1990-08-14),

Title: Yang-I Lin: An Innovator in Pharmaceutical Research

Introduction

Yang-I Lin is a distinguished inventor based in Nanuet, NY, with an impressive portfolio of 47 patents. His work primarily focuses on pharmaceutical innovations aimed at addressing various health issues. Lin's contributions are crucial in the ongoing battle against bacterial infections and diseases mediated by inflammatory processes.

Latest Patents

Two of Lin's latest patents include:

1. **Bicyclic 6-alkylidene-penems as β-lactamase inhibitors** - This invention presents a compound designed to combat bacterial infections, providing a unique structure intended for pharmaceutical compositions that are beneficial for patients in need.

2. **Beta-sulfonamide hydroxamic acid inhibitors of TACE/matrix metalloproteinase** - This patent covers compounds that are effective in treating a range of diseases such as rheumatoid arthritis, diabetes, and multiple sclerosis. The invention emphasizes methods for using these compounds to alleviate symptoms of various ailments.

Career Highlights

Throughout his career, Yang-I Lin has made significant contributions while working with notable companies in the pharmaceutical sector. His experiences at American Cyanamid Company and Wyeth have bolstered his expertise and influence in pharmaceutical research and development.

Collaborations

Lin has collaborated with esteemed professionals, including Panayota Bitha and Joseph J Hlavka. These collaborations have enhanced the scope and impact of his innovations, driving forward advancements in drug development.

Conclusion

Yang-I Lin's dedication to innovation in the pharmaceutical industry has resulted in numerous patents that pave the way for new treatments and improved patient outcomes. His ongoing work continues to inspire and enhance the field of medical research.